XL-ing at Induction of Apoptosis in Kidney Cancer through Inhibition of BCL-XL.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 35984355.
- Also identified by DOI 10.1158/1078-0432.CCR-22-2104 and PMC identifier 9633424.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Through analysis of the cancer dependency map of CRISPR and short hairpin RNA datasets, the antiapoptotic BCL-XL was found to be a selective dependency in kidney cancer. Among kidney cancers, BCL-XL inhibition is most active in those with a mesenchymal gene signature, which portends a poor prognosis and response to current therapies. See related article by Grubb et al., p. 4689.
Medical subject headings
- Apoptosis
- Kidney Neoplasms